Aptamers Market Size - By Type (DNA, RNA-Based Aptamers), Application (Research & Development, Diagnostics), Technology (SELEX), End-use & Global Forecast, 2024 – 2032

Aptamers Market Size - By Type (DNA, RNA-Based Aptamers), Application (Research & Development, Diagnostics), Technology (SELEX), End-use & Global Forecast, 2024 – 2032

Aptamers Market Size

Aptamers Market size accounted for USD 2.9 billion in 2023 and is estimated to grow at 20.3% to reach USD 15.1 billion by 2032. Distinct advantages that aptamers offer over traditional antibodies are driving the rapid development of the industry.
 

Aptamers, with their unique characteristics of high specificity and affinity for target molecules, are poised to revolutionize various industries, particularly in healthcare and biotechnology. Also, unlike antibodies, aptamers can be easily synthesized and chemically modified, enabling swift optimization for specific applications. This scalability ensures efficient and cost-effective production, expediting research and development processes. Moreover, aptamers' small size, low immunogenicity, and ease of customization result in enhanced target binding and reduced off-target effects.
 

Aptamers are short, single-stranded DNA, RNA, or peptide molecules that are selected from large libraries of random sequences through a process known as systematic evolution of ligands by exponential enrichment (SELEX). Aptamers have a unique three-dimensional structure that allows them to specifically bind to target molecules, such as proteins, nucleic acids, small molecules, or cells, with high affinity and selectivity.
 

COVID-19 Impact

The emergence of the COVID-19 pandemic had a positive impact on aptamers market. As the global healthcare group rapidly responded to the urgent need for diagnostic tools and therapeutics, aptamers emerged as a versatile solution. Their ability to bind to specific targets enabled the development of rapid and sensitive diagnostic assays, swiftly and accurately for detecting the virus. Moreover, aptamers have also demonstrated potential in neutralizing the virus by inhibiting its interaction with human cells. This newfound application potential has attracted substantial research funding and collaboration from both public and private sectors.
 

Aptamers Market Trends

The increasing prevalence of chronic and rare diseases will boost the industry gains. For instance, according to the American Cancer Society report, in 2022, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. alone. As the burden of these conditions continues to rise, the demand for innovative and targeted therapeutic solutions becomes increasingly urgent. Therefore, aptamers, with versatile nature enables the development of precision therapies tailored to the unique characteristics of each ailment, paving the way for more effective treatment strategies. Also, the flexibility of aptamers in targeting diverse disease markers, enable to opt for precision medicine approaches.
 

Aptamers Restraint

The aptamers market faces a significant challenge due to the low awareness levels and incomplete regulatory policies. Despite their immense potential, aptamers remain relatively lesser known compared to other biotechnologies. This lack of awareness among healthcare professionals, researchers, and potential end-users can impede the industry expansion by limiting adoption and investment. Moreover, the absence of comprehensive and well-established regulatory frameworks specifically tailored for aptamers can introduce uncertainty and hurdles in their development and commercialization processes. Also, the evolving nature of aptamer technology often falls outside the scope of traditional regulations, leading to inconsistencies and delays in approvals.
 

Aptamers Market Analysis

By type, the aptamers market is classified into DNA-based aptamers, RNA-based aptamers, and XNA-based aptamers. The DNA-based aptamers segment accounted for 63.4% of the industry share in 2022. DNA-based aptamers, derived from DNA sequences, offer a versatile and well-established platform for a wide array of applications. Their unique characteristics, such as stability, cost-effectiveness, and ease of synthesis, have increased their demand in healthcare industry. Furthermore, recent progress in the development, purification, and targeted delivery of aptamers to eliminate specific cells has captured the interest of numerous researchers.
 

Based on application, the aptamers market is segmented into research & development, diagnostics, therapeutics, and other applications. The research & development segment accounted for 35.6% of the industry share in 2022. With an increasing focus on innovation and cutting-edge solutions, aptamers have emerged as a powerful resource within the R&D landscape. The adaptability of aptamers, coupled with ongoing advancements in selection methodologies and customization techniques, has captured the attention of both academia and industry players. Moreover, collaborative efforts between researchers, biotechnology firms, and institutions are fostering an environment of exploration and discovery. For instance, in June 2021, SomaLogic collaborated with Ixaka Ltd to support the discovery and development of aptamers based bispecific therapeutics.
 

Based on technology, the aptamers market is segmented into SELEX, X-aptamers, and other technologies. The SELEX segment is projected to witness significant progressF of 19.9% by 2032. SELEX's unique capability to systematically identify high-affinity aptamers for diverse targets offers a strategic advantage in the development of aptamer-based solutions. Also, SELEX involves a methodical process of selection, amplification, and refinement, empowering researchers to craft aptamers for precise binding. Moreover, the continuous enhancements in SELEX methodologies coupled with SELEX's role in enabling the creation of innovative diagnostics, therapeutics, and research tools has fuelled its widespread adoption.
 

Based on end-use, the aptamers market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, research institutes, and other end-users. The pharmaceutical & biotechnology companies segment is projected to witness significant growth of 20.3% by 2032. Increasing investments in pharmaceutical research & development will significantly drive the aptamer industry by catalysing innovation and accelerating the development of aptamer-based solutions. For instance, in June 2018, Aptamer Group Ltd received USD 2.2 million from Meneldor, a biopharmaceutical investment company and other overseas investors. This fund was utilized to drive preclinical discovery programs involving the development of aptamer drug conjugates.
 

North America aptamers market accounted for 43.6% industry share in 2022. The region's well-established pharmaceutical and biotechnology industry, along with the presence of prominent research institutes, academic centers, and well-funded healthcare initiatives. Moreover, the growing prevalence of chronic diseases such as cancer, cardiovascular disease (CVD) and age-related macular degeneration (AMD). Additionally, the region's proactive regulatory landscape and supportive policies facilitate efficient development, validation, and commercialization of aptamer-based products.
 

Aptamers Market Share

Major industry players operating in the aptamers market include

• SomaLogic
• Aptamer Group
• Aptadel Therapeutics
• Base Pair Biotechnologies
• Vivonics Inc.
   

Aptamers Industry News

• In January 2023, Aptamer Group partnered with BaseCure Therapeutics to develop new targeted gene therapies. This partnership helps to identify specific cell types that might be developed as potential delivery vehicles for siRNA uptake into target cells and tissues. This strategy helped the company to create new opportunities for the expansion of aptamer applications in the field of therapeutics.
   
• In June 2021, Ixaka Ltd collaborated with SomaLogic to support the development of aptamer-based bispecific therapeutics. The collaboration evaluated the safety and efficacy of antigen specific SOMAmer reagents previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamer. This strategy helped the company to enhance its aptamer-based bispecific therapeutics.
   

The aptamers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Type

• DNA-based aptamers
• RNA-based aptamers
• XNA-based aptamers

By Application  

• Research & development
• Diagnostics
• Therapeutics
• Other applications

By Technology  

• SELEX
• X-aptamers
• Other technologies

By End-use

• Pharmaceutical & biotechnology companies
• Academic & government research institutes
• CROs
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa